Physician profile
Leatrice A Olson
NPI 1447268198
$8,659.93
in general payments reported to CMS, 2019-2025
32 companies · $681 in 2025
The $681 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $1,433 · 2021: $1,937 · 2022: $1,177 · 2023: $1,091 · 2024: $986 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.80 |
| Education | $211.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,158.95 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $978.68 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $974.30 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $923.42 | 2019-2025 | Farxiga, Bevespi Aerosphere, Xigduo |
| Lilly USA, LLC | $620.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $596.56 | 2021-2025 | |
| Novo Nordisk INC | $404.21 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $379.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Actelion Pharmaceuticals US, INC. | $290.00 | 2023-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $267.62 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.41 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $202.67 | 2019-2025 | Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $193.20 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.98 | 2020-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $170.97 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $169.36 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.80 | 2022 | |
| Mylan Specialty L.P. | $132.38 | 2019-2023 | Yupelri |
| Glaxosmithkline, LLC. | $126.20 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $108.78 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $90.74 | 2019-2024 | Eliquis |
| Sunovion Pharmaceuticals INC. | $86.41 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $38.02 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $31.00 | 2025 | Recorlev |
| Ironwood Pharmaceuticals, INC | $26.74 | 2020 | |
| Phathom Pharmaceuticals, INC. | $24.00 | 2024 | Voquezna |
| Medtronic, INC. | $15.83 | 2025 | Minimed 780g |
| Therapeuticsmd, INC. | $15.33 | 2021 | |
| Biodelivery Sciences International, INC. | $15.23 | 2020 | |
| Insulet Corporation | $15.03 | 2023 | Omnipod |
| Novartis Pharmaceuticals Corporation | $13.17 | 2019 | |
| Boston Scientific Corporation | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leatrice Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.